Biotech billionaire Kirk has a new, much bigger top line in mind

Randal "RJ" Kirk has made billions in the biotech business by focusing on the development of new and improved drugs. But now the CEO of synthetic biotech pioneer Intrexon ($XON) is thinking outside the healthcare box. "Biotech has a reverse footprint on the world. You should think beyond healthcare because if you want to know where the rapid growth in biotech is going to occur, it's going to be, in my opinion, highest in consumer, second highest in industrial, third highest in agriculture and then therapeutics," he told an audience in Florida. Story

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.